Literature DB >> 27484772

Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology.

Miro Šimun Alebić1, Nataša Stojanović2, Dinka Pavičić Baldani3, Lea Smirčić Duvnjak4.   

Abstract

This cross-sectional study aimed to investigate the association between menstrual cycle lenght and metabolic parameters in non-hyperandrogenic women with polycystic ovarian morphology, n = 250. Metabolic profiles of all participants were evaluated using anthropometric parameters (body mass index, waist circumference), parameters of dyslipidemia (total cholesterol, HDL-cholesterol, triglycerides) and markers of insulin resistance (fasting insulin, homeostasis model assessment for insulin resistance index). The associations between menstrual cycle lenght and cardiometabolic risk factors such as insulin resistance, dyslipidemia, and obesity were investigated. In non-hyperandrogenic women with polycystic ovarian morphology, menstrual cycle lenght was associated with hypertriglyceridemia and insulin resistance independently of body mass index. Moreover, menstrual cycle lenght added value to body mass index in predicting hypertriglyceridemia. The optimal menstrual cycle lenght cut-off value for identifying of non-hyperandrogenic women with polycystic ovarian morphology at metabolic risk was found to be 45 days. Metabolic profile of non-hyperandrogenic women with polycystic ovarian morphology (n = 75) with menstrual cycle lenght >45 days was similar to that of hyperandrogenic women with polycystic ovarian morphology (n = 138) while metabolic profile of non-hyperandrogenic women with polycystic ovarian morphology with menstrual cycle lenght ≤45 days (n = 112) was similar to that of controls (n = 167). Non-hyperandrogenic women with polycystic ovarian morphology with menstrual cycle lenght >45 days had higher prevalence of cardiometabolic risk factors compared to those with menstrual cycle lenght ≤45 days. Non-hyperandrogenic women with polycystic ovarian morphology are not metabolically homogeneous. Menstrual cycle lenght is an easy-to-obtain clinical parameter positively associated with the probability of unfavorable metabolic status in non-hyperandrogenic women with polycystic ovarian morphology. Menstrual cycle lenght cut-off value of 45 days was found to have the best capacity in discriminating non-hyperandrogenic women with polycystic ovarian morphology with and without metabolic derangement(s) corroborating in favor of the cardiometabolic risk factors screening and management in non-hyperandrogenic women with polycystic ovarian morphology with menstrual cycle lenght >45 days through strategies for prevention of cardiovascular disease.

Entities:  

Keywords:  Anovulation; Insulin resistance; Menstrual cycle; Polycystic ovary syndrome; Triglycerides

Mesh:

Year:  2016        PMID: 27484772     DOI: 10.1007/s12020-016-1062-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  50 in total

1.  Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.

Authors:  Thomas M Barber; John A H Wass; Mark I McCarthy; Stephen Franks
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04       Impact factor: 3.478

Review 2.  The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research.

Authors:  Julian H Barth; Ephia Yasmin; Adam H Balen
Journal:  Clin Endocrinol (Oxf)       Date:  2007-08-29       Impact factor: 3.478

3.  The role of AMH in anovulation associated with PCOS: a hypothesis.

Authors:  Roy Homburg; Giselle Crawford
Journal:  Hum Reprod       Date:  2014-04-25       Impact factor: 6.918

Review 4.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

5.  Hirsutism: implications, etiology, and management.

Authors:  R Hatch; R L Rosenfield; M H Kim; D Tredway
Journal:  Am J Obstet Gynecol       Date:  1981-08-01       Impact factor: 8.661

6.  Accuracy of reporting of menstrual cycle length.

Authors:  Anne Marie Zaura Jukic; Clarice R Weinberg; Allen J Wilcox; D Robert McConnaughey; Paige Hornsby; Donna D Baird
Journal:  Am J Epidemiol       Date:  2007-10-10       Impact factor: 4.897

7.  Assessment of anovulation in eumenorrheic women: comparison of ovulation detection algorithms.

Authors:  Kristine E Lynch; Sunni L Mumford; Karen C Schliep; Brian W Whitcomb; Shvetha M Zarek; Anna Z Pollack; Elizabeth R Bertone-Johnson; Michelle Danaher; Jean Wactawski-Wende; Audrey J Gaskins; Enrique F Schisterman
Journal:  Fertil Steril       Date:  2014-05-27       Impact factor: 7.329

8.  Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome.

Authors:  Dimitrios Panidis; Konstantinos Tziomalos; Panagiotis Chatzis; Efstathios Papadakis; Dimitrios Delkos; Elena A Tsourdi; Eleni A Kandaraki; Ilias Katsikis
Journal:  Eur J Endocrinol       Date:  2013-01-17       Impact factor: 6.664

9.  Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.

Authors:  Bart C J M Fauser; Basil C Tarlatzis; Robert W Rebar; Richard S Legro; Adam H Balen; Roger Lobo; Enrico Carmina; Jeffrey Chang; Bulent O Yildiz; Joop S E Laven; Jacky Boivin; Felice Petraglia; C N Wijeyeratne; Robert J Norman; Andrea Dunaif; Stephen Franks; Robert A Wild; Daniel Dumesic; Kurt Barnhart
Journal:  Fertil Steril       Date:  2011-12-06       Impact factor: 7.329

Review 10.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Authors:  M John Chapman; Henry N Ginsberg; Pierre Amarenco; Felicita Andreotti; Jan Borén; Alberico L Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Børge G Nordestgaard; Kausik K Ray; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen; Gerald F Watts
Journal:  Eur Heart J       Date:  2011-04-29       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.